



CLINICAL GUIDELINE

BGCS & BMS Management of menopausal symptoms following treatment for gynaecological cancer

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Version Number:	1
Does this version include changes to clinical advice:	N/A
Date Approved:	6 th August 2025
Date of Next Review:	31 st August 2027
Lead Author:	British Gynaecological Cancer Society and British Menopause Society
Approval Group:	Gynaecology Clinical Governance Group
Guideline ID Number:	1228

Important Note:

The online version of this document is the only version that is maintained.
Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.